Raymond James Upgrades ARS Pharmaceuticals to Strong Buy, Raises Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Ryan Deschner has upgraded ARS Pharmaceuticals (NASDAQ:SPRY) from Outperform to Strong Buy and raised the price target from $18 to $22.
August 13, 2024 | 9:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James has upgraded ARS Pharmaceuticals (NASDAQ:SPRY) from Outperform to Strong Buy and increased the price target from $18 to $22.
The upgrade to Strong Buy and the increased price target from a reputable analyst at Raymond James is likely to positively impact investor sentiment and drive short-term price appreciation for ARS Pharmaceuticals.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100